Lev S, Yarden Y, Givol D
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
J Biol Chem. 1992 Aug 5;267(22):15970-7.
The protooncogene c-kit encodes a tyrosine kinase receptor for the stem cell factor (SCF). Mutants of c-kit were shown to confer a pleiotropic defective phenotype and often display negative dominance in heterozygous mice. To explore the involvement of receptor dimerization in this genetic phenomenon, we employed both a human ligand, which does not recognize the murine receptor, and a rodent SCF, which binds to the human receptor with 100-fold reduced affinity as compared with human SCF. SCF binding to living cells was found to induce rapid and complete receptor dimerization that involved activation of the catalytic tyrosine kinase function. Although receptor dimerization can be attributed to the dimeric nature of the ligand, no dissociation of Kit dimers occurred at high excess of SCF, suggesting that receptor-receptor interactions are also involved in dimer stabilization. This was supported by in vitro formation of heterodimers between the human and murine Kit proteins through monovalent binding of species-specific human SCF. By coexpression of human and mouse Kit in murine fibroblasts, we found that receptor heterodimerization in living cells involved an increase in the affinity of human Kit for rat SCF and also an accelerated rate of receptor down-regulation. When a human Kit mutant lacking the kinase insert domain was coexpressed with the murine wild-type receptor, we observed a significant decrease in both the activation of the intact tyrosine kinase and its coupling to an effector protein, namely phosphatidylinositol 3'-kinase. Our results favor a receptor activation model that assumes an initial step of monovalent ligand binding, followed by an intermediate receptor dimer bound by one arm of the ligand molecule. This model predicts the existence of an intrinsic receptor dimerization site and provides a structural basis for genetic dominance of mutant SCF receptors.
原癌基因c-kit编码一种干细胞因子(SCF)的酪氨酸激酶受体。c-kit的突变体表现出多效性缺陷表型,并且在杂合小鼠中常呈现负显性。为了探究受体二聚化在这一遗传现象中的作用,我们使用了一种不识别鼠类受体的人类配体以及一种啮齿动物SCF,后者与人类受体的结合亲和力相比于人类SCF降低了100倍。研究发现,SCF与活细胞结合可诱导快速且完全的受体二聚化,这涉及催化酪氨酸激酶功能的激活。尽管受体二聚化可归因于配体的二聚体性质,但在SCF大量过量时未发生Kit二聚体的解离,这表明受体-受体相互作用也参与二聚体的稳定。通过物种特异性人类SCF的单价结合在体外形成人源和鼠源Kit蛋白之间的异源二聚体,证实了这一点。通过在鼠成纤维细胞中共表达人源和鼠源Kit,我们发现活细胞中的受体异源二聚化涉及人源Kit对大鼠SCF亲和力的增加以及受体下调速率的加快。当一个缺乏激酶插入结构域的人源Kit突变体与鼠源野生型受体共表达时,我们观察到完整酪氨酸激酶的激活及其与效应蛋白即磷脂酰肌醇3'-激酶的偶联均显著降低。我们的结果支持一种受体激活模型,该模型假定单价配体结合为初始步骤,随后是由配体分子的一条臂结合的中间受体二聚体。该模型预测存在一个内在的受体二聚化位点,并为突变型SCF受体的遗传显性提供了结构基础。